CHARLOTTE MIZUTA: Open Payments
NPI 1437791381 · SANTA ANA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$529 in 19 payments from 7 companies in 2025. Trend: 2023 $345 · 2024 $398 · 2025 $529
Food & beverage: $529
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $168 |
| Alkermes, Inc. | 5 | $129 |
| E.R. Squibb & Sons, L.L.C. | 3 | $73 |
| Janssen Pharmaceuticals, Inc | 2 | $60 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Otsuka America Pharmaceutical, Inc. | 1 | $26 |
| Luye Pharma (USA) Ltd. | 1 | $17 |
Products named: INGREZZA, ARISTADA, COBENFY, INVEGA SUSTENNA, FANAPT, ABILIFY ASIMTUFII, ERZOFRI EXTENDED-RELEASE.
Industry payments across CA — which companies pay providers there.
